A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
作者： Harold R Collard , Williamson Z Bradford , Vincent Cottin , Kevin R Flaherty , Talmadge E King
DOI: 10.1183/09031936.00200614
关键词: Clinical trial 、 Idiopathic pulmonary fibrosis 、 Intensive care medicine 、 Late phase 、 Early phase 、 Alternative medicine 、 Pathology 、 Medicine 、 Drug development
摘要: … key considerations that the authors view as central to future progress in IPF clinical trials (… are described that we believe will lead to more effective and efficient clinical trials in IPF in the …
sci-hub.se 参考文章(39)
Leslie C. Watters, Talmadge E. King, Marvin I. Schwarz, James A. Waldron, Ray E. Stanford, Reuben M. Cherniack, A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. The American review of respiratory disease. ,vol. 133, pp. 97- 103 ,(1986) , 10.1164/ARRD.1986.133.1.97
TALMADGE E. KING, JANET A. TOOZE, MARVIN I. SCHWARZ, KEVIN R. BROWN, REUBEN M. CHERNIACK, Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. American Journal of Respiratory and Critical Care Medicine. ,vol. 164, pp. 1171- 1181 ,(2001) , 10.1164/AJRCCM.164.7.2003140
Harold R Collard, Kevin K Brown, Fernando J Martinez, Ganesh Raghu, Rhonda S Roberts, Kevin J Anstrom, None, Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis Chest. ,vol. 146, pp. 1256- 1262 ,(2014) , 10.1378/CHEST.14-0492
Hengrui Sun, Beth A. Davison, Gad Cotter, Michael J. Pencina, Gary G. Koch, Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials Analyzing Data Using a Global Method Circulation-heart Failure. ,vol. 5, pp. 742- 749 ,(2012) , 10.1161/CIRCHEARTFAILURE.112.969154
Ganesh Raghu, Harold R Collard, Kevin J Anstrom, Kevin R Flaherty, Thomas R Fleming, Talmadge E King Jr, Fernando J Martinez, Kevin K Brown, None, Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials American Journal of Respiratory and Critical Care Medicine. ,vol. 185, pp. 1044- 1048 ,(2012) , 10.1164/RCCM.201201-0006PP
A. Guenther, , The European IPF Network: towards better care for a dreadful disease European Respiratory Journal. ,vol. 37, pp. 747- 748 ,(2011) , 10.1183/09031936.00012111
Benjamin R. Saville, Amy H. Herring, Gary G. Koch, A Robust Method for comparing Two Treatments in a Confirmatory Clinical Trial via Multivariate Time-to-event Methods that jointly incorporate Information from Longitudinal and Time-to-event Data Statistics in Medicine. ,vol. 29, pp. 75- 85 ,(2009) , 10.1002/SIM.3740
Anna L Peljto, Yingze Zhang, Tasha E Fingerlin, Shwu-Fan Ma, Joe GN Garcia, Thomas J Richards, Lori J Silveira, Kathleen O Lindell, Mark P Steele, James E Loyd, Kevin F Gibson, Max A Seibold, Kevin K Brown, Janet L Talbert, Cheryl Markin, Karl Kossen, Scott D Seiwert, Elissa Murphy, Imre Noth, Marvin I Schwarz, Naftali Kaminski, David A Schwartz, None, Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis JAMA. ,vol. 309, pp. 2232- 2239 ,(2013) , 10.1001/JAMA.2013.5827
Dianne M. Finkelstein, David A. Schoenfeld, Combining mortality and longitudinal measures in clinical trials Statistics in Medicine. ,vol. 18, pp. 1341- 1354 ,(1999) , 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7
Gary G. Koch, Sonia M. Davis, Randy L. Anderson, Methodological advances and plans for improving regulatory success for confirmatory studies Statistics in Medicine. ,vol. 17, pp. 1675- 1690 ,(1998) , 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1675::AID-SIM970>3.0.CO;2-C